ATE450547T1 - Eml4-alk-fusionsgen - Google Patents
Eml4-alk-fusionsgenInfo
- Publication number
- ATE450547T1 ATE450547T1 AT07254044T AT07254044T ATE450547T1 AT E450547 T1 ATE450547 T1 AT E450547T1 AT 07254044 T AT07254044 T AT 07254044T AT 07254044 T AT07254044 T AT 07254044T AT E450547 T1 ATE450547 T1 AT E450547T1
- Authority
- AT
- Austria
- Prior art keywords
- fusion gene
- cancer
- present
- eml4
- polynucleotide
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 4
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 108700020796 Oncogene Proteins 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006277718 | 2006-10-11 | ||
| JP2007120670 | 2007-05-01 | ||
| CA 2598893 CA2598893C (en) | 2006-10-11 | 2007-08-24 | Eml4-alk fusion gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE450547T1 true ATE450547T1 (de) | 2009-12-15 |
Family
ID=39277176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07254044T ATE450547T1 (de) | 2006-10-11 | 2007-10-11 | Eml4-alk-fusionsgen |
Country Status (7)
| Country | Link |
|---|---|
| US (7) | US7728120B2 (de) |
| EP (1) | EP2116553B1 (de) |
| JP (2) | JP4303303B2 (de) |
| AT (1) | ATE450547T1 (de) |
| CA (1) | CA2598893C (de) |
| DE (1) | DE602007003543D1 (de) |
| ES (2) | ES2515170T3 (de) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
| US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| EP3266867A1 (de) * | 2006-04-14 | 2018-01-10 | Cell Signaling Technology, Inc. | Gendefekte und mutante alk-kinase in festen menschlichen tumoren |
| CA2598893C (en) * | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| CN101466721B (zh) * | 2007-04-13 | 2013-08-21 | 细胞信号技术公司 | 在人实体瘤中的基因缺损和突变体alk激酶 |
| TWI389893B (zh) * | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| AU2009215168A1 (en) * | 2008-02-12 | 2009-08-20 | Dana-Farber Cancer Institute | Fish assay for EML4 and ALK fusion in lung cancer |
| JP2009219728A (ja) * | 2008-03-18 | 2009-10-01 | Daito Giken:Kk | 遊技台 |
| MX2010012703A (es) | 2008-05-21 | 2010-12-21 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| CA2762108A1 (en) * | 2009-05-15 | 2010-11-18 | Insight Genetics, Inc. | Methods and compositions relating to fusions of alk for diagnosing and treating cancer |
| JPWO2011043220A1 (ja) | 2009-10-06 | 2013-03-04 | 富士レビオ株式会社 | 融合遺伝子の測定方法 |
| US9175350B2 (en) * | 2009-12-22 | 2015-11-03 | Quest Diagnostics Investments Incorporated | EML4-ALK translocations in lung cancer |
| EP2540822B1 (de) * | 2010-02-22 | 2017-05-03 | Fujirebio Inc. | Verfahren zur identifikation von tumoren, verfahren zur herstellung von zellen zur expression von tumoren und verfahren zum screening nach substanzen zur anzielung von tumoren |
| US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
| TW201202703A (en) * | 2010-04-16 | 2012-01-16 | Response Genetics Inc | Primers, probes, methods, and kits for the detection of EML4-ALK variants |
| WO2012019132A2 (en) | 2010-08-06 | 2012-02-09 | Cell Signaling Technology, Inc. | Anaplastic lymphoma kinase in kidney cancer |
| BR112013003879B1 (pt) | 2010-08-20 | 2020-12-22 | Chugai Seiyaku Kabushiki Kaisha | composição compreendendo compostos tetracíclicos e formulação oralmente administrável que a compreende |
| US8962245B2 (en) | 2010-09-02 | 2015-02-24 | Kurume University | Method for producing circular DNA formed from single-molecule DNA |
| JP2014005206A (ja) * | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
| JP5769952B2 (ja) * | 2010-11-12 | 2015-08-26 | 株式会社Ｌｓｉメディエンス | Ｅｍｌ４−ａｌｋ融合遺伝子の高感度検出方法 |
| WO2012075318A2 (en) * | 2010-12-01 | 2012-06-07 | Cell Signaling Technology, Inc. | Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer |
| BR112013019643B1 (pt) * | 2011-02-02 | 2022-04-19 | Novartis Ag | Uso de inibidores de álcali |
| US20140296181A1 (en) * | 2011-04-07 | 2014-10-02 | Coferon, Inc. | Methods of modulating oncogenic fusion proteins |
| BR112013027734A2 (pt) | 2011-05-04 | 2017-08-08 | Ariad Pharma Inc | compostos para a inibição de proliferação celular em cânceres impulsionados pelo egfr, método e composição farmacêutica |
| EP2752486B1 (de) | 2011-08-31 | 2016-12-28 | Kurume University | Verfahren zur exklusiven auswahl von zirkularisierter dna aus monomolekularer dna bei der zirkularisierung von dna-molekülen |
| DK2838998T3 (en) | 2012-04-18 | 2018-01-15 | Cell Signaling Technology Inc | EGFR AND ROS1 IN CANCER |
| AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| US9084456B1 (en) * | 2012-05-28 | 2015-07-21 | Jack Zemer | Linkage for jewelry components |
| EP2892536B1 (de) | 2012-09-06 | 2019-12-18 | Epizyme, Inc. | Verfahren zur behandlung von leukämie |
| CA2894220A1 (en) * | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Dot1l inhibitors for use in the treatment of leukemia |
| EP2958592A1 (de) | 2013-02-22 | 2015-12-30 | F. Hoffmann-La Roche AG | Verfahren zur behandlung von krebs und zur verhinderung von arzneimittelresistenz |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| JP6534930B2 (ja) | 2013-07-26 | 2019-06-26 | 公益財団法人がん研究会 | Ｎｔｒｋ３融合体の検出法 |
| WO2015064620A1 (ja) * | 2013-10-29 | 2015-05-07 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| WO2015064621A1 (ja) * | 2013-10-29 | 2015-05-07 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| EP3098312B1 (de) | 2014-01-24 | 2023-07-19 | Japanese Foundation For Cancer Research | Neuartiges fusionselement und verfahren zur detektion davon |
| CN106458967A (zh) | 2014-04-25 | 2017-02-22 | 中外制药株式会社 | 四环化合物的新结晶 |
| CN106456651A (zh) | 2014-04-25 | 2017-02-22 | 中外制药株式会社 | 以高用量含有四环性化合物的制剂 |
| TWI718102B (zh) | 2014-08-08 | 2021-02-11 | 日商中外製藥股份有限公司 | ４環性化合物的非晶質體 |
| US10597725B2 (en) * | 2014-09-01 | 2020-03-24 | Arkray, Inc. | Primer reagent for amplifying ALK fusion gene, ALK fusion gene amplification reagent kit including the same, and ALK fusion gene amplification method and ALK fusion gene analysis method using the same |
| JP7015171B2 (ja) | 2016-01-15 | 2022-02-02 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| JP6740172B2 (ja) * | 2017-05-02 | 2020-08-12 | セル・シグナリング・テクノロジー・インコーポレイテツド | ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ |
| US12473548B2 (en) * | 2018-06-27 | 2025-11-18 | City Of Hope | Modification of small RNAs for therapeutic uses |
| EP3815688B1 (de) | 2018-06-29 | 2023-12-06 | Chugai Seiyaku Kabushiki Kaisha | Pharmazeutische zusammensetzung enthaltend ein schwerlösliches basisches medikament |
| JP7385191B2 (ja) * | 2019-08-30 | 2023-11-22 | 学校法人同志社 | Ｅｍｌ４－ａｌｋ阻害ペプチドおよびこれを含む肺がん治療薬 |
| JP2020156481A (ja) * | 2020-04-06 | 2020-10-01 | セル・シグナリング・テクノロジー・インコーポレイテツド | ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ |
| CN118159274A (zh) | 2021-10-28 | 2024-06-07 | 中外制药株式会社 | 糖浆剂 |
| TW202412771A (zh) | 2022-07-04 | 2024-04-01 | 日商中外製藥股份有限公司 | 併用醫藥 |
| CN119789871A (zh) | 2022-08-30 | 2025-04-08 | 中外制药株式会社 | 并用药物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2338210T3 (es) | 1999-11-11 | 2010-05-05 | Astellas Pharma Inc. | Metaloproteasa novedosa que tiene actividad agrecanasa. |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| CA2532800C (en) | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| BR122019017579B8 (pt) | 2003-08-15 | 2021-07-27 | Novartis Ag | 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica |
| CA2559866A1 (en) | 2004-03-31 | 2005-10-20 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| CA2598893C (en) * | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| CN101466721B (zh) * | 2007-04-13 | 2013-08-21 | 细胞信号技术公司 | 在人实体瘤中的基因缺损和突变体alk激酶 |
| TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
-
2007
- 2007-08-24 CA CA 2598893 patent/CA2598893C/en active Active
- 2007-08-27 US US11/845,498 patent/US7728120B2/en active Active
- 2007-10-11 EP EP20090006058 patent/EP2116553B1/de active Active
- 2007-10-11 AT AT07254044T patent/ATE450547T1/de not_active IP Right Cessation
- 2007-10-11 ES ES09006058.3T patent/ES2515170T3/es active Active
- 2007-10-11 DE DE200760003543 patent/DE602007003543D1/de active Active
- 2007-10-11 ES ES07254044T patent/ES2335368T3/es active Active
- 2007-10-11 JP JP2007265917A patent/JP4303303B2/ja active Active
-
2008
- 2008-04-10 US US12/100,595 patent/US7605131B2/en active Active
-
2009
- 2009-02-18 JP JP2009035918A patent/JP5172736B2/ja active Active
- 2009-05-15 US US12/466,920 patent/US7964710B2/en active Active
-
2011
- 2011-04-13 US US13/086,245 patent/US8197818B2/en active Active
-
2012
- 2012-05-10 US US13/468,730 patent/US9029521B2/en active Active
-
2015
- 2015-03-10 US US14/643,181 patent/US9932589B2/en active Active
-
2017
- 2017-11-13 US US15/810,918 patent/US20180066266A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20110230545A1 (en) | 2011-09-22 |
| US20100240673A1 (en) | 2010-09-23 |
| US20150184161A1 (en) | 2015-07-02 |
| ES2515170T3 (es) | 2014-10-29 |
| JP4303303B2 (ja) | 2009-07-29 |
| US8197818B2 (en) | 2012-06-12 |
| EP2116553B1 (de) | 2014-07-30 |
| US7605131B2 (en) | 2009-10-20 |
| US20080090776A1 (en) | 2008-04-17 |
| US20130158095A1 (en) | 2013-06-20 |
| JP2008295444A (ja) | 2008-12-11 |
| US9029521B2 (en) | 2015-05-12 |
| DE602007003543D1 (de) | 2010-01-14 |
| US7964710B2 (en) | 2011-06-21 |
| JP2009100783A (ja) | 2009-05-14 |
| EP2116553A1 (de) | 2009-11-11 |
| CA2598893A1 (en) | 2008-04-11 |
| US9932589B2 (en) | 2018-04-03 |
| ES2335368T3 (es) | 2010-03-25 |
| US20090099193A1 (en) | 2009-04-16 |
| JP5172736B2 (ja) | 2013-03-27 |
| CA2598893C (en) | 2012-04-10 |
| US20180066266A1 (en) | 2018-03-08 |
| US7728120B2 (en) | 2010-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE450547T1 (de) | Eml4-alk-fusionsgen | |
| EA200702203A1 (ru) | Способы и нуклеиновые кислоты для анализов клеточных пролиферативных нарушений | |
| DE602005009702D1 (de) | Esr1 und gebärmutterhalskrebs | |
| ATE514090T1 (de) | Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen | |
| WO2008088854A3 (en) | Genetic markers for predicting responsiveness to combination therapy | |
| TW200745556A (en) | Biomarkers for liver fibrotic injury | |
| NZ593289A (en) | Anti-neuropilin-1 antibodies for treating angiogenesis | |
| WO2013033629A3 (en) | Methods and compositions for the treatment and diagnosis of colorectal cancer | |
| MX2012001716A (es) | Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf. | |
| WO2008140774A3 (en) | Methods for diagnosing and treating prostate and lung cancer | |
| ATE511645T1 (de) | Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme | |
| EA200970695A1 (ru) | Способы и нуклеиновые кислоты для анализов нарушений клеточной пролиферации | |
| WO2008012362A3 (en) | New protein isoforms and uses thereof | |
| WO2008073629A3 (en) | Bifunctional predictors of cancer treatment sensitivity and resistance | |
| WO2008073177A3 (en) | Expression profiles associated with irinotecan treatment | |
| WO2007103146A3 (en) | Truncated proteins as cancer markers | |
| IL188036A0 (en) | Methods and apparatus for improving the sensitivity of capillary zone electrophoresis | |
| TW200626900A (en) | Wnt proteins and detection and treatment of cancer | |
| IL179441A0 (en) | Hif prolyl hydroxylase activity assay | |
| MX2009004382A (es) | Variaciones geneticas asociadas con tumores. | |
| DK1912066T3 (da) | Hjælpemetode til diagnose og terapi af cancer med nucleolin | |
| WO2004074441A3 (en) | Amplification or overexpression of mll septin-like fusion (msf) and septin9 and methods related thereto | |
| ATE462803T1 (de) | Kit und verfahren zum nachweis von urothelkarzinom | |
| WO2006085746A3 (en) | Diagnosis of metastases in hnscc tumours | |
| DK1694697T3 (da) | Overfladelokaliserede Campylobacter jejuni-polypeptider |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |